Keyphrases
Advanced Gastric Cancer
80%
Endoscopic Ultrasound-guided Fine-needle Aspiration (EUS-FNA)
76%
Gastric Cancer
59%
Franseen Needle
57%
Pathological Diagnosis
42%
Intestine
42%
Inflammation
42%
Colorectal Cancer
42%
Nivolumab
42%
Gastrointestinal Cancer
34%
Differential Diagnosis
34%
Immune Checkpoint Inhibitors
31%
Risk Factors
31%
CD8+ T Cells
31%
Methylation
29%
Diarrhea
28%
ULK2
28%
Fluoropyrimidine
28%
Intestinal mucosal Injury
28%
Chemotherapy-induced Diarrhea
28%
Commensal
28%
Anticancer Immunity
28%
Ectopic Colonization
28%
Hepatic Angiomyolipoma
28%
Endoscopic Ultrasound Guided Biopsy
28%
Biopsy Needle
28%
Hepatocellular Carcinoma
28%
Intensive Surveillance
28%
Surveillance Colonoscopy
28%
Constitutional Mismatch Repair Deficiency (CMMRD)
28%
19-gauge
28%
Oral Bacteria
28%
Ultrasound Examination
28%
Gastrointestinal Tumours
28%
Portal Phase
28%
Retrospective Analysis
28%
Solid Pancreatic Lesions
28%
Klebsiella
28%
Immune-related Adverse Events
28%
Deficiency Cases
28%
Poor Differentiation
28%
Duodenal Stenosis
28%
Epithelial-mesenchymal Transition
28%
Endoscopic Ultrasound
28%
T Helper 1
28%
Histological Samples
28%
Urothelial Carcinoma
28%
Pembrolizumab
28%
Fine-needle Aspiration Biopsy
28%
Tumor
23%
Medicine and Dentistry
Endoscopic Ultrasound Guided Fine Needle Biopsy
79%
Abdominal Cancer
71%
Endoscopic Ultrasound
57%
Fine-Needle Aspiration
57%
Nivolumab
42%
Biopsy Technique
42%
Neoplasm
39%
Diagnosis
35%
Differential Diagnosis
32%
Immune-Related Adverse Events
30%
Hepatocellular Carcinoma
28%
Angiomyolipoma
28%
N [bis(1 Aziridinyl)phosphinyl] 4 Iodobenzamide
28%
Magnetic Resonance Imaging
28%
Duodenum Stenosis
28%
DNA Mismatch Repair
28%
Pembrolizumab
28%
Endoscopy
28%
Peritoneum Metastasis
28%
Transitional Cell Carcinoma
28%
Gastrointestinal Tumor
28%
Colorectal Carcinoma
22%
Pancreas Cancer
19%
Liver Tumor
19%
Pentetic Acid
19%
Immune Checkpoint Inhibitor
17%
Overall Survival
17%
Colectomy
16%
Binimetinib
14%
Tail
14%
Linitis Plastica
14%
Carbohydrate Antigen
14%
Patient Characteristics
14%
Blood Clot
14%
TRPV4
14%
Hydronephrosis
14%
Liver Metastasis
14%
MEK Inhibitor
14%
Duodenum
14%
Constipation
14%
Monotherapy
14%
Biological Marker
14%
Exudative Retinal Detachment
14%
Ramucirumab
14%
Progression Free Survival
13%
Metastatic Carcinoma
12%
Polyp
12%
Esophagogastroduodenoscopy
11%
Diagnostic Accuracy
11%
Retinal Detachment
9%
Pharmacology, Toxicology and Pharmaceutical Science
Abdominal Cancer
100%
Nivolumab
50%
Chemotherapy
46%
Adverse Event
42%
Diarrhea
35%
Immune Checkpoint Inhibitor
31%
Pembrolizumab
30%
Injury
28%
Fluoropyrimidine
28%
Peritoneum Metastasis
28%
Digestive System Cancer
28%
Overall Survival
27%
Combination Therapy
21%
Constipation
21%
Progression Free Survival
19%
Ramucirumab
16%
Disseminated Intravascular Clotting
14%
Esophagus Cancer
14%
Tumor Necrosis Factor
14%
Liver Metastasis
14%
Mitogen Activated Protein Kinase Kinase Inhibitor
14%
Monotherapy
14%
Diseases
14%
Irritable Colon
14%
Taxane
14%
Carbohydrate Antigen
14%
Colorectal Carcinoma
14%
Normal Human
14%
Dysphagia
14%
Clinical Trial
14%
Retina Detachment
14%
Biological Marker
14%
Escherichia coli
11%
Binimetinib
10%
Primary Tumor
7%
Dysbiosis
7%
Prospective Study
7%
Ascites
7%
Retrospective Study
5%
Butyrate
5%
Microflora
5%
Intestine Flora
5%
Folic Acid
5%